• Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (PubMed=8557231).
  

PubMed=2227544; DOI=10.1016/0090-8258(90)90068-V
Benjamin Bonavida, Toshiharu Tsuchitani, Jacob Zighelboim, Jonathan S. Berek;
Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Gynecol. Oncol. 38:333-339(1990)

PubMed=1918981; DOI=10.4049/jimmunol.147.8.2609
Hideki Morimoto, Jeffrey T. Safrit, Benjamin Bonavida;
Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.
J. Immunol. 147:2609-2616(1991)

PubMed=8557231; DOI=10.1006/gyno.1996.0014
Jeffrey S. Skilling, Robert C. Squatrito, Joseph P. Connor, Theodore Niemann, Richard E. Buller;
p53 gene mutation analysis and antisense-mediated growth inhibition of human ovarian carcinoma cell lines.
Gynecol. Oncol. 60:72-80(1996)

PubMed=9554442; DOI=10.1093/jnci/90.8.597
Anita Lyn Sabichi, Denver T. Hendricks, Mary A. Bober, Michael J. Birrer;
Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide.
J. Natl. Cancer Inst. 90:597-605(1998)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677
Christopher T. Korch, Monique A. Spillman, Twila A. Jackson, Britta M. Jacobsen, Susan K. Murphy, Bruce Arthur Lessey, Virgil Craig Jordan, Andrew Peter Bradford;
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)